Thank you for subscribing!
Finfeed Archived Aug 11, 2020
Japan is an important market for clinical stage regenerative medicine company, Regeneus Ltd (ASX: RGS), which has just negotiated a license agreement with Kyocera Corporation (Kyocera, TYO:6971) to develop and commercialise Progenza for Knee Osteoarthritis (Progenza OA) in Japan.
Finfeed Archived Mar 23, 2020
The US Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for clinical-stage regenerative medicine company Regeneus Ltd's (ASX: RGS) lead stem cell platform technology Progenza.
Next Investors Archived Mar 02, 2020
Biotech company Regeneus (ASX:RGS) is a regenerative medicine company, and the therapy is a novel stem cell therapy.
Get expert stock analysis direct in your inbox
Join Our Mailing List
